756520-70-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Development:
4-(2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine is used as a building block in organic synthesis for the development of new pharmaceuticals and agrochemicals. Its unique structure allows it to be a key component in the creation of novel compounds with potential therapeutic and agricultural benefits.
Used in Polymer and Material Manufacturing:
In the manufacturing industry, 4-(2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine is utilized in the production of polymers and materials. Its incorporation into these products can enhance their properties, such as stability, durability, and performance.
Used in Organic Electronics and Optoelectronics:
4-(2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine is also used in the field of organic electronics and optoelectronics. Its interesting electronic properties make it a promising candidate for applications in devices such as solar cells, light-emitting diodes, and transistors, where its unique characteristics can contribute to improved performance and efficiency.
Overall, 4-(2-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine is a versatile chemical with a wide range of potential uses in various industries, including pharmaceuticals, materials science, and electronics. Its unique structure and properties make it a valuable asset in the development of innovative products and technologies.

Upstream product

• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 214360-76-6 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 73183-34-3 bis(pinacol)diborane 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 591-20-8 3-Bromophenol 
• 622-40-2 2-(morpholin-4-yl)ethanol 
• 46230-78-8 2-(morpholin-1-yl)ethyl methanesulfonate 

Downstream Products

• 1202918-37-3 5-chloro-3-((5-(3-(2-morpholinoethoxy)phenyl)furan-2-yl)methylene)indolin-2-one 
• 1595291-59-0 tert-butyl 1H-indazol-5-yl(2-(3-(2-morpholinoethoxy)phenyl)pyrimidin-4-yl)carbamate 
• 1595290-14-4 N-(2-(3-(2-morpholinoethoxy)phenyl)pyrimidin-4-yl)-1H-indazol-5-amine 

Relevant academic research and scientific papers

MACROCYCLIC COMPOUNDS AND USES THEREOF

Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan

FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study that ibrutinib (9) exhibited selective and moderate inhibitory activity against FLT3-ITD positive AML cel

TREATMENT OF GVHD

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

TREATMENT OF OCULAR DISORDERS

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.

Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.